Silence Therapeutics (NASDAQ:SLN) Sees Large Volume Increase – Here’s What Happened

Shares of Silence Therapeutics PLC Sponsored ADR (NASDAQ:SLN) saw strong trading volume on Tuesday . Approximately 448,209 shares traded hands during trading, a decline of 5% from the previous session’s volume of 472,318 shares.The stock last traded at $15.01 and had previously closed at $15.43.

Key Stories Impacting Silence Therapeutics

Here are the key news stories impacting Silence Therapeutics this week:

• Positive Sentiment: Morgan Stanley reiterated a bullish view, maintaining an Overweight rating and issuing a Buy recommendation. The firm’s stance reinforces the positive analyst outlook for Silence’s siRNA pipeline and could support valuation. Morgan Stanley maintains Overweight rating on Silence Therapeutics
• Positive Sentiment: Several analyst roundups describe healthcare investors as bullish on SLN, while a separate report says the stock has a consensus rating of “Moderate Buy.” This indicates that Wall Street sentiment remains generally favorable despite recent volatility. Analysts Are Bullish on Top Healthcare Stocks
• Positive Sentiment: Silence discussed top-line results from the Phase II SANRECO trial of divesiran in polycythemia vera. The update keeps investor focus on a potentially important clinical asset, though the investment impact depends on the detailed efficacy and safety data. SANRECO Phase II Trial Slideshow
• Neutral Sentiment: The company priced an upsized underwritten public offering of 12,962,963 ADSs at $13.50 each, raising approximately $175 million before expenses. The proceeds improve funding for clinical programs, but the transaction also increases the share count. Silence Therapeutics Announces Pricing of Upsized $175 Million Underwritten Public Offering
• Negative Sentiment: The offering creates near-term dilution and may weigh on the stock, particularly with the deal priced close to the prevailing market level. Silence also recently reported a larger-than-expected quarterly loss, adding another concern for investors focused on cash burn and execution.

Analyst Upgrades and Downgrades

Several research firms recently issued reports on SLN. HC Wainwright restated a “buy” rating and issued a $75.00 price target on shares of Silence Therapeutics in a research note on Wednesday, June 17th. Cantor Fitzgerald initiated coverage on Silence Therapeutics in a research report on Wednesday, June 24th. They set an “overweight” rating on the stock. Weiss Ratings reissued a “sell (d-)” rating on shares of Silence Therapeutics in a report on Friday, July 17th. Finally, Morgan Stanley boosted their target price on shares of Silence Therapeutics from $25.00 to $32.00 and gave the company an “overweight” rating in a research report on Tuesday. One equities research analyst has rated the stock with a Strong Buy rating, four have given a Buy rating and one has assigned a Sell rating to the company. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average target price of $53.50.

Silence Therapeutics Stock Down 7.7%

The firm has a market capitalization of $641.52 million, a P/E ratio of -10.61 and a beta of 1.39. The firm has a 50 day moving average of $9.80 and a 200-day moving average of $7.37.

Silence Therapeutics (NASDAQ:SLN) last posted its quarterly earnings data on Monday, August 10th. The company reported ($0.26) EPS for the quarter, missing analysts’ consensus estimates of ($0.14) by ($0.12). Silence Therapeutics had a negative return on equity of 96.82% and a negative net margin of 8,943.86%. As a group, research analysts expect that Silence Therapeutics PLC Sponsored ADR will post -1.08 EPS for the current year.

Institutional Investors Weigh In On Silence Therapeutics

Several institutional investors and hedge funds have recently bought and sold shares of the company. Boothbay Fund Management LLC grew its stake in Silence Therapeutics by 1.0% during the second quarter. Boothbay Fund Management LLC now owns 252,421 shares of the company’s stock worth $1,464,000 after buying an additional 2,409 shares in the last quarter. Massar Capital Management LP acquired a new position in shares of Silence Therapeutics in the 2nd quarter valued at approximately $115,000. UBS Group AG raised its position in shares of Silence Therapeutics by 34.5% in the 3rd quarter. UBS Group AG now owns 307,363 shares of the company’s stock valued at $1,595,000 after buying an additional 78,854 shares in the last quarter. Two Sigma Investments LP lifted its holdings in shares of Silence Therapeutics by 6.6% during the 3rd quarter. Two Sigma Investments LP now owns 63,247 shares of the company’s stock worth $328,000 after acquiring an additional 3,935 shares during the period. Finally, Citadel Advisors LLC bought a new stake in shares of Silence Therapeutics during the 3rd quarter worth approximately $112,000. Institutional investors own 98.73% of the company’s stock.

About Silence Therapeutics

Silence Therapeutics plc is a clinical-stage biotechnology company focused on the discovery and development of ribonucleic acid interference (RNAi) therapeutics. Leveraging its proprietary EnCore lipid nanoparticle delivery platform, the company aims to silence disease-causing genes in the liver and other tissues. Silence’s technology is designed to enhance targeted delivery of small interfering RNA (siRNA) molecules, with the goal of achieving durable therapeutic effects and improved safety profiles compared with traditional drug modalities.

The company’s lead product candidates include SLN360, an siRNA therapeutic designed to reduce lipoprotein(a) levels for cardiovascular risk reduction, and SLN124, aimed at treating hereditary hemochromatosis and beta-thalassemia by modulating iron metabolism.